Shire Sees Baxalta Deal Closing as Expected After New Rules

  • Transaction expected to complete by mid-2016 as plannned
  • New Treasury rules had thwarted Pfizer-Allergan deal

Shire Plc expects to close its $32 billion deal to acquire Baxalta Inc. in mid-2016 as expected, after new rules from the U.S. Treasury thwarted the $160 billion merger of Pfizer Inc. and Allergan Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.